PMID- 37881499
OWN - NLM
STAT- MEDLINE
DCOM- 20231027
LR  - 20231027
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Role of glycolysis in inflammatory bowel disease and its associated colorectal 
      cancer.
PG  - 1242991
LID - 10.3389/fendo.2023.1242991 [doi]
LID - 1242991
AB  - Inflammatory bowel disease (IBD) has been referred to as the "green cancer," and 
      its progression to colorectal cancer (CRC) poses a significant challenge for the 
      medical community. A common factor in their development is glycolysis, a crucial 
      metabolic mechanism of living organisms, which is also involved in other 
      diseases. In IBD, glycolysis affects gastrointestinal components such as the 
      intestinal microbiota, mucosal barrier function, and the immune system, including 
      macrophages, dendritic cells, T cells, and neutrophils, while in CRC, it is 
      linked to various pathways, such as phosphatidylinositol-3-kinase (PI3K)/AKT, 
      AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and 
      transcription factors such as p53, Hypoxia-inducible factor (HIF), and c-Myc. 
      Thus, a comprehensive study of glycolysis is essential for a better understanding 
      of the pathogenesis and therapeutic targets of both IBD and CRC. This paper 
      reviews the role of glycolysis in diseases, particularly IBD and CRC, via its 
      effects on the intestinal microbiota, immunity, barrier integrity, signaling 
      pathways, transcription factors and some therapeutic strategies targeting 
      glycolytic enzymes.
CI  - Copyright (c) 2023 Xia, Zhang, Ocansey, Tu, Mao and Sheng.
FAU - Xia, Yuxuan
AU  - Xia Y
AD  - Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, 
      School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast 
      University, Nanjing, Jiangsu, China.
FAU - Ocansey, Dickson Kofi Wiredu
AU  - Ocansey DKW
AD  - Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, 
      School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
AD  - Directorate of University Health Services, University of Cape Coast, Cape Coast, 
      Ghana.
FAU - Tu, Qiang
AU  - Tu Q
AD  - Clinical Laboratory, Nanjing Jiangning Hospital, Nanjing, Jiangsu, China.
FAU - Mao, Fei
AU  - Mao F
AD  - Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, 
      School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
FAU - Sheng, Xiumei
AU  - Sheng X
AD  - Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, 
      School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231010
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Humans
MH  - *Inflammatory Bowel Diseases
MH  - Signal Transduction
MH  - *Colorectal Neoplasms/etiology
MH  - Transcription Factors
MH  - Glycolysis
PMC - PMC10595037
OTO - NOTNLM
OT  - colorectal cancer
OT  - glycolysis
OT  - immunity
OT  - inflammatory bowel disease
OT  - intestinal
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/10/26 06:42
MHDA- 2023/10/27 06:43
PMCR- 2023/01/01
CRDT- 2023/10/26 04:12
PHST- 2023/06/20 00:00 [received]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/10/27 06:43 [medline]
PHST- 2023/10/26 06:42 [pubmed]
PHST- 2023/10/26 04:12 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1242991 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Oct 10;14:1242991. doi: 
      10.3389/fendo.2023.1242991. eCollection 2023.